Gilead Sciences, Inc. GILD
150.93
1.24
0.83%
as of 25 Sep
- Market cap
- $183.2B
- P/E
- 0.0×
Follow GILD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Gilead Sciences, Inc. (GILD) Current ratio
Gilead Sciences, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 1.3×, down 0.3× from fiscal 2025 (1.6×). Over the past ten years it has ranged from 1.3× (fiscal 2021) to 3.4× (fiscal 2018); the current reading is higher than 45% of that period. That is in line with the Drug Manufacturers General industry median of 1.3× and below the Healthcare sector median of 3.0×.
Current ratio, annual
Annual
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 1.6× | (2.79%) |
| FY2024 | 1.6× | 12.01% |
| FY2023 | 1.4× | 10.95% |
| FY2022 | 1.3× | 1.01% |
| FY2021 | 1.3× | (9.34%) |
| FY2020 | 1.4× | (54.79%) |
| FY2019 | 3.1× | (8.13%) |
| FY2018 | 3.4× | 23.55% |
| FY2017 | 2.7× | 28.71% |
| FY2016 | 2.1× | (15.13%) |
Quarterly
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 1.3× | (35.68%) |
| Mar 2026 | 2.0× | 26.70% |
| Dec 2025 | 1.6× | 6.83% |
| Sep 2025 | 1.5× | 10.49% |
| 42 more quarters | Free account |
Against its own ten years
Low 1.3×
High 3.4×
Ten-year median
1.6×
Current reading's percentile
45
Current ratio against peers
| Company | Current ratio |
|---|---|
| BMY Bristol Myers Squibb Company compare | 1.5× |
| AMGN Amgen Inc. compare | 1.4× |
| PFE Pfizer Inc. compare | 1.3× |
| GILD Gilead Sciences, Inc. | 1.3× |
| SNY Sanofi compare | 1.0× |
| AZN AstraZeneca PLC compare | 0.9× |
| NVO Novo Nordisk A/S compare | 0.9× |
| NVS Novartis AG compare | 0.9× |
| GSK GSK PLC Sponsored ADR compare | 0.8× |
| Drug Manufacturers General industry median | 1.3× |
| Healthcare sector median | 3.0× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on GILD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement